NCT01621581View on ClinicalTrials.gov

AAV2-GDNF for Advanced Parkinson s Disease

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 13, 2013

Primary Completion Date

February 4, 2022

Study Completion Date

February 4, 2022

Conditions

Parkinson's Disease

Interventions

GENETIC

Convection enhanced delivery/AAV2-GDNF

Adeno-Associated Virus Encoding Glial Cell Line-Derived Neurotrophic Factor (AAV2-GDNF) Administered via Bilateral Stereotactic Convection-Enhanced Delivery

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors

lead

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

NCT01621581 - AAV2-GDNF for Advanced Parkinson s Disease | Biotech Hunter | Biotech Hunter